Form 4: Syros Pharmaceuticals CFO Jason Haas Reports Stock Transactions
SEC Form 4 Filing
Chief Financial Officer of Syros Pharmaceuticals, Jason Haas, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On October 31, 2024, Jason Haas, the CFO of Syros Pharmaceuticals, reported transactions involving the company's common stock.
- 18,875 shares were acquired upon the vesting of restricted stock units.
- 5,624 shares were disposed of to cover tax withholding obligations at a price of $2.09 per share.
- Following these transactions, Haas directly owns 137,803 shares of Syros Pharmaceuticals common stock.
- The restricted stock units were granted on October 6, 2022, and vested in two equal installments on October 31, 2023, and October 31, 2024.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly shift investor sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices involving stock-based compensation.
Key Dates
| Date | Description |
|---|---|
| October 6, 2022 | Date of restricted stock unit award grant. |
| October 31, 2023 | First vesting date of restricted stock units (50%). |
| October 31, 2024 | Date of transactions: vesting of remaining restricted stock units and tax withholding. |
| November 04, 2024 | Date of Form 4 filing. |
Keywords
Syros Pharmaceuticals, Jason Haas, CFO, Form 4, Stock, Restricted Stock Units, Vesting, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.